|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia.
|
16417409 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increases in postprandial apoCIII after fructose, but not glucose consumption, are positively associated with elevated triglycerides in large triglyceride-rich lipoproteins and increased small dense LDL levels.
|
31789670 |
2020 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Likelihood ratio test showed a strong interaction for increasing risk of early IHD between the presence of ApoC3 and 9p21.3 locus with hypertriglyceridemia (p=0.0008, 0.0011) as well as between 9p21.3 locus and smoking (p=0.0010) after correction for multiple testing.
|
24656450 |
2014 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Logistic regression analysis of these four SNPs revealed that, carriage of the APOA5 c.56 G allele (odd ratios 4.49) and the APOA5 c.-3 G allele (odds ratio 3.23) were strong independent predictors of hypertriglyceridaemia (P < 0.001), whereas in contrast, carriage of the APOC3 c102 T allele (odds ratio 1.35) and the APOC3 c.340 G allele (odds ratio 1.37), did not show any significant effects that were independent of APOA5.
|
16125709 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Particularly, the variants rs632153, rs633389, rs2187126 and rs1263163 might be risk conferring to dyslipidemia by elevating LDLC and TC levels, while the variants of APOC3 and APOA1 genes might be the genetic determinants of elevated triglycerides in the present population.
|
28610615 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at a level of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo high density lipoprotein (HDL) cholesterolemia 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p<0.001 for area under the receiver-operating characteristic curve).
|
27713142 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia.
|
8696957 |
1996 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Recently identified polymorphisms in the apoC3 (T-455C, C-482T), and cholesteryl ester transfer protein (CETP) (B1/B2 allele) genes are associated with increased triglycerides and reduced high-density lipoprotein (HDL)-levels, a feature now also common among Asian Indians.
|
12476935 |
2002 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RRFs were obtained by ethanol extraction from Rosa rugosa Thunb.. Transgenic mice expressing human Apolipoprotein C3 (ApoC3) were used as a mouse model of hypertriglyceridemia.
|
31100436 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Several polymorphisms in the apolipoprotein C-III (apoC-III) gene have been associated with hypertriglyceridemia, but the link with coronary artery disease risk is still controversial.
|
12235176 |
2002 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Several polymorphisms in the apolipoprotein C3 (APOC3) gene have been found association with hypertriglyceridemia(HTG), but the link with coronary heart disease(CHD) risk between ethnicities was still controversial.
|
22054125 |
2011 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Several therapies for regulating TRL metabolism, including inhibitors of diacylglycerol O-acyltransferase and microsomal triglyceride transfer protein, and apoC-III antisense oligonucleotides, merit further investigation in patients with hypertriglyceridaemia.
|
24060958 |
2013 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The S2 allele genotyped patients had a significantly increased triglyceride level (P < 0.001) and increased triglycerides were observed among both patient and control CC genotype carriers.
|
19701693 |
2010 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The apoC-III Gln38Lys variant was identified in subjects of Mexican origin with moderate hypertriglyceridemia.
|
28887372 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).
|
28441154 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The less common allele (S2) of the SstI polymorphism on the 3' untranslated region of the APOC3 gene has been previously associated with increased triglycerides, total cholesterol (TC), and apoCIII levels and cardiovascular risk on several, but not all, studies.
|
11500189 |
2001 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The polymorphic sites were the SstI site in the apoCIII 3' untranslated region, whose presence has previously been shown to be associated with hypertriglyceridemia (HTG) in Caucasians, and the MspI site in the third intron of the apoAI gene.
|
7705829 |
1995 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The presence of the ApoC3 CC haplotype was associated with increased triglycerides in patients treated with olanzapine or clozapine.
|
17726453 |
2008 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
|
30073766 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The variant apo CIII promoter is common in the human population and may represent a major contributing factor to the development of hypertriglyceridemia.
|
8675624 |
1995 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Therefore, although the individual risk of hypertriglyceridemia is increased in women with the haplotype T, C at -482, -455, it appears that the -482, -455 and SstI APOC-III gene polymorphisms are not major contributors to the risk of dyslipidemia in the population of northern France.
|
10781646 |
2000 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, there appears to be a need for effective TG-lowering agents.<b>Areas covered</b>: This review presents the most recent advances in hypertriglyceridemia treatment; specifically, it discusses the results of clinical trials and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.<b>Expert opinion</b>: In the era of extreme lowering of LDL-C levels with several agents, there seems to be space for novel therapeutic options to combat parameters responsible for residual CVD risk, among which are elevated TGs.
|
31738617 |
2020 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well.
|
11483625 |
2001 |
|
Hypertriglyceridemia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These results demonstrate that none of the 5' apoCIII polymorphisms can account for the association of the apoCIII gene locus with hypertriglyceridemia and, moreover, owing to linkage disequilibrium, raise the possibility that the region conferring susceptibility maps downstream, rather than upstream, of the apoCIII gene promoter sequences.
|
8882875 |
1996 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that apoCIII and/or hypertriglyceridemia plays a major role in liver inflammation and cell death, which in turn increases susceptibility to and the severity of diet-induced NAFLD.
|
28163820 |
2017 |